Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-02-22FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Granules Pharmaceuticals' generic four-salt amphetamine combination (dextroamphetamine saccharat…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD [Phase 3]
Phase 3 trial updating efficacy and safety data for methylphenidate hydrochloride extended-release capsules in children and adolescents with…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD [Phase 4]
Phase 4 trial update evaluating flexible-dose titration of Aptensio XR in young children (ages 4 to under 6) with ADHD has completed with re…
-
FDA approval · 2023-02-15FDA Approved: ATOMOXETINE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for a generic Atomoxetine product from Strides Pharma Science Limited, enabling market entry of …
-
FDA approval · 2023-02-07FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application from Sandoz Inc for a generic product containing four amphetamine salts (dextroamphetamine saccharat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder [Phase 2]
Phase 2 trial updating safety and efficacy of OPC-34712 as a complementary therapy for adults with Attention Deficit Hyperactivity Disorder …
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD [NA]
Clinical trial update reporting termination with posted results for an fMRI study comparing stimulant versus non-stimulant treatment in ADHD…
-
FDA approval · 2023-01-23FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved Granules Pharmaceuticals' generic combination amphetamine product containing dextroamphetamine saccharate, amphetamine aspartat…
-
FDA approval · 2023-01-19FDA Approved: ATOMOXETINE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for atomoxetine hydrochloride from Apotex Corp., approving a generic version of the ADHD medication.
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) [Phase 2]
Phase 2 open-label pharmacokinetics study of Centanafadine extended-release capsules in pediatric ADHD participants completed with results p…
-
FDA approval · 2022-12-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride from XLCare Pharmaceuticals, Inc., establishing a generic version …
-
FDA approval · 2022-12-20FDA Approved: ATOMOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Atomoxetine (generic) submitted by Aurobindo Pharma Limited.
-
FDA approval · 2022-12-16FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' supplemental application for methylphenidate hydrochloride (generic). This approval authorizes the manufac…
-
FDA approval · 2022-12-16FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Neolpharma, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride (Neolpharma, Inc.) under an ANDA, granting regulatory approval for…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting [Phase 3]
A Phase 3 clinical trial evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children aged …
-
FDA approval · 2022-11-30FDA Approved: MIXED SALTS OF A SINGLE ENTITY AMPHETAMINE PRODUCT XR — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for Mixed Salts of a Single Entity Amphetamine Product XR, a generic extended-release amphetamine pr…
-
CLINICAL_TRIALS trial_result · 2022-11-01Clinical Trial Update: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) [Phase 3]
Phase 3 trial (CHIME 1) evaluating treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment has c…
-
FDA approval · 2022-10-14FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) filed by NextWave Pharmaceuticals, Inc., granting regulatory appro…
-
FDA approval · 2022-09-21FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (KVK-TECH, INC.)
FDA approved a supplemental application for methylphenidate hydrochloride from KVK-Tech, Inc., a generic stimulant used to treat attention-d…
-
FDA approval · 2022-09-16FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceutical Inc)
FDA approved Camber Pharmaceutical Inc.'s supplemental application for methylphenidate hydrochloride (generic) under an Abbreviated New Drug…
-
FDA approval · 2022-09-14FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Supplemental Application (Dr. Reddy's Laboratories Inc)
The FDA approved a supplemental application for methylphenidate hydrochloride (LA) from Dr. Reddy's Laboratories Inc. This action supports t…
-
FDA approval · 2022-09-06FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Cranbury Pharmaceuticals, LLC)
The FDA approved a supplemental application for methylphenidate hydrochloride (generic product) from Cranbury Pharmaceuticals, LLC. This app…
-
FDA approval · 2022-08-18FDA Approved: DEXTROAMPHETAMINE SULFATE — Original Application (Cranbury Pharmaceuticals, LLC)
FDA has approved Cranbury Pharmaceuticals' original application for a generic dextroamphetamine sulfate product. The approval covers its use…
-
FDA approval · 2022-08-16FDA Approved: XELSTRYM — Supplemental Application (Noven Therapeutics, LLC)
The FDA approved a supplemental application for XELSTRYM (dextroamphetamine) submitted by Noven Therapeutics, LLC.
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children [Phase 4]
Phase 4 clinical trial update investigating multi neuro-functional biomarkers to monitor treatment effects in children with ADHD.